- | Country :
- France
- | organs : -
- | Specialty : -
Extract
This is a prospective multicenter phase II trial of gemcitabine, cisplatin, and ifosfamide (GIP) in patients with relapsed non-seminomatous germ-cell tumors (NSGCT) and a predicted favorable prognosis.
Inclusion criteria
- Germ Cell Tumor